A
$ Value
$0
Shares
38,300
Price
$0
Filed
Apr 20
Insider
Name
Clyburn Frank
Title
—
CIK
0001763963
Roles
Director
Transaction Details
Transaction Date
2026-04-16
Code
A
Table
Derivative
Ownership
Direct
Equity Swap
No
Shares After
38,300
Footnotes
The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to the Reporting Person's continued service through each such vesting date.
Filing Info
Clyburn Frank's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-04-16 | KLRA | A | $0 |
| 2025-06-26 | RVMD | A | $0 |
| 2025-06-26 | RVMD | A | $0 |
| 2024-08-05 | RVMD | A | $0 |
Other Insiders at KLRA (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
| Kaplan Andrew T. / BAIN CAPITAL INVESTORS LLC | $134.4M | — | 2026-04-20 |
| Bain Capital Life Sciences Investors, LLC / Koppel Adam | $25.0M | — | 2026-04-20 |
| RTW INVESTMENTS, LP | $8.0M | — | 2026-04-20 |
| BAIN CAPITAL INVESTORS LLC | — | — | 2026-04-20 |
| MILLIGAN JOHN F | — | — | 2026-04-16 |
|
Renaud Ronald C JR
CEO & President
|
— | — | 2026-04-16 |
| MACKAY MARTIN | — | — | 2026-04-16 |
| Koppel Adam | — | — | 2026-04-20 |
|
Pagan Douglas W.
Chief Financial Officer
|
— | — | 2026-04-16 |
| Bain Capital Life Sciences Investors, LLC | — | — | 2026-04-20 |
|
Burgess Paul D.
See Remarks
|
— | — | 2026-04-16 |
|
Cloghessy Paula
Chief People Officer
|
— | — | 2026-04-16 |
| Kaplan Andrew T. | — | — | 2026-04-20 |
| Hite Christopher | — | — | 2026-04-16 |
|
Akamine Scott
Chief Legal Officer
|
— | — | 2026-04-16 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | — | — | 2026-04-20 |
|
Coleman Jamie Beth
Chief Commercial Officer
|
— | — | 2026-04-16 |
|
Wasserman Scott M.
Chief Medical Officer
|
— | — | 2026-04-16 |